PTGX Relative Valuation
PTGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PTGX is overvalued; if below, it's undervalued.
Historical Valuation
Protagonist Therapeutics Inc (PTGX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 27.01 is considered Undervalued compared with the five-year average of -18.81. The fair price of Protagonist Therapeutics Inc (PTGX) is between 243.58 to 338.29 according to relative valuation methord. Compared to the current price of 57.33 USD , Protagonist Therapeutics Inc is Undervalued By 76.46%.
Relative Value
Fair Zone
243.58-338.29
Current Price：57.33
76.46%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
5.09
P/B
Median3y
3.85
Median5y
4.05
9.78
FCF Yield
Median3y
-4.97
Median5y
-6.87
Competitors Valuation Multiple
The average P/S ratio for PTGX's competitors is 439.88, providing a benchmark for relative valuation. Protagonist Therapeutics Inc Corp (PTGX) exhibits a P/S ratio of 27.06, which is -93.85% above the industry average. Given its robust revenue growth of -88.89%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Protagonist Therapeutics Inc (PTGX) currently overvalued or undervalued?
What is Protagonist Therapeutics Inc (PTGX) fair value?
How does PTGX's valuation metrics compare to the industry average?
What is the current P/B ratio for Protagonist Therapeutics Inc (PTGX) as of Jul 18 2025?
What is the current FCF Yield for Protagonist Therapeutics Inc (PTGX) as of Jul 18 2025?
What is the current Forward P/E ratio for Protagonist Therapeutics Inc (PTGX) as of Jul 18 2025?